HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Journal Volume
41
Journal Issue
35
Date Issued
2023-12-10
Author(s)
Yu, Helena A
Goto, Yasushi
Hayashi, Hidetoshi
Felip, Enriqueta
Reck, Martin
Yoh, Kiyotaka
Lee, Se-Hoon
Paz-Ares, Luis
Besse, Benjamin
Bironzo, Paolo
Kim, Dong-Wan
Johnson, Melissa L
Wu, Yi-Long
John, Thomas
Kao, Steven
Kozuki, Toshiyuki
Massarelli, Erminia
Patel, Jyoti
Smit, Egbert
Reckamp, Karen L
Dong, Qian
Shrestha, Pomy
Fan, Pang-Dian
Patel, Parul
Sporchia, Andrea
Sternberg, David W
Sellami, Dalila
Jänne, Pasi A
Abstract
Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and safety of HER3-DXd in patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC).
SDGs
Type
journal article